HomeCompareCKNQP vs ABBV

CKNQP vs ABBV: Dividend Comparison 2026

CKNQP yields 6.20% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $46.5K in total portfolio value
10 years
CKNQP
CKNQP
● Live price
6.20%
Share price
$100.00
Annual div
$6.20
5Y div CAGR
18%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55.9K
Annual income
$7,910.72
Full CKNQP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CKNQP vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCKNQPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CKNQP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CKNQP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CKNQP
Annual income on $10K today (after 15% tax)
$527.00/yr
After 10yr DRIP, annual income (after tax)
$6,724.11/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $14,331.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CKNQP + ABBV for your $10,000?

CKNQP: 50%ABBV: 50%
100% ABBV50/50100% CKNQP
Portfolio after 10yr
$79.1K
Annual income
$16,341.24/yr
Blended yield
20.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CKNQP
No analyst data
Altman Z
0.1
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CKNQP buys
0
ABBV buys
0
No recent congressional trades found for CKNQP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCKNQPABBV
Forward yield6.20%3.06%
Annual dividend / share$6.20$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR18%40.6%
Portfolio after 10y$55.9K$102.3K
Annual income after 10y$7,910.72$24,771.77
Total dividends collected$30.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CKNQP vs ABBV ($10,000, DRIP)

YearCKNQP PortfolioCKNQP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,432$731.60$11,550$430.00$118.00ABBV
2$13,154$922.31$13,472$627.96$318.00ABBV
3$15,245$1,170.39$15,906$926.08$661.00ABBV
4$17,808$1,495.91$19,071$1,382.55$1.3KABBV
5$20,982$1,927.04$23,302$2,095.81$2.3KABBV
6$24,955$2,503.87$29,150$3,237.93$4.2KABBV
7$29,986$3,284.08$37,536$5,121.41$7.5KABBV
8$36,436$4,351.84$50,079$8,338.38$13.6KABBV
9$44,819$5,831.69$69,753$14,065.80$24.9KABBV
10$55,867$7,910.72$102,337$24,771.77$46.5KABBV

CKNQP vs ABBV: Complete Analysis 2026

CKNQPStock

CoBank, ACB, a cooperative bank, provides financial products and services in the United States. It operates through three segments: Agribusiness, Farm Credit Banking, and Rural Infrastructure. The company offers various loan products, such as intermediate- and long-term loans, revolving term loans, interim and bridge loans, construction loans, short-term lines of credit, and acquisitions financing. It also provides lease financing and related services for a range of ag production and forestry equipment; grain, feed, fertilizer, and seed; storage and handling; building and bins; material handling and construction; packaging and processing; transportation; and utility, communication, and energy. In addition, the company offers trade finance products, including commercial and standby letters of credit, documentary collections, and pre-export financing. Further, it provides interest rate caps and swaps; capital market services comprising debt capital raising, secondary market trading, deal structuring and pricing advice, and post-closing administrative agency services; and cash management services, including payables, receivables, information reporting, liquidity, and fraud management, as well as online banking, mobile banking, and commercial credit card solutions. Additionally, the company owns and leases mineral interests located in Arizona, California, Colorado, Kansas, Nevada, New Mexico, Oklahoma, and Utah. It serves agricultural cooperatives; other food and agribusiness companies; rural power, communications, and water cooperatives and companies; rural community facilities; agricultural credit associations; farmer-owned financial institutions; and other businesses that serve agriculture and rural communities. The company was founded in 1916 and is headquartered in Greenwood Village, Colorado.

Full CKNQP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CKNQP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CKNQP vs SCHDCKNQP vs JEPICKNQP vs OCKNQP vs KOCKNQP vs MAINCKNQP vs JNJCKNQP vs MRKCKNQP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.